Efficacy and Safety of Second‐Line Immune Checkpoint Inhibitor Rechallenge in Advanced or Metastatic Esophageal Squamous Cell Carcinoma: A Retrospective Study

ABSTRACT Background Immune checkpoint inhibitor (ICI) has reshaped the treatment landscape of esophageal squamous cell carcinoma (ESCC). But most patients end up with disease progression and/or therapeutic intolerance. The subsequent ICI rechallenge raises some discussions. Methods A retrospective s...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Wensi Zhao, Nan Zhao, Dedong Cao
Format:	Artigo
Jezik:	Inglês
Izdano:	Wiley 2025-07-01
Serija:	Thoracic Cancer
Teme:	esophageal squamous cell carcinoma immune checkpoint inhibitor overall survival rechallenge second‐line setting
Online dostop:	https://doi.org/10.1111/1759-7714.70131
Oznake:	Označite Brez oznak, prvi označite!